OncoPoint

OncoPoint logo
March 2nd 2016, het Pand, Ghent University, Ghent, Belgium

We kindly invite you to the 4th OncoPoint research seminar on Wednesday March 2nd, 2016.

Basic, translational and clinical cancer researchers from Ghent University, UGent-VIB and Ghent University Hospital will present their new work.

OncoPoint's aim is to provide a common interface and substrate to meet fellow cancer researchers and discuss, exchange information, and start collaborations.

2014-06-16

UZ Letters interview with prof. De Wever regarding OncoPoint and its mission to bring together cancer researchers at U(Z)Gent (in Dutch)

Program 2016

08:45 - 09:00
Opening
Keynote speaker
09:00 - 09:45
Frederic Amant (KULeuven)
Patient-Derived Tumor Xenograft Models: an emerging way to personalized medicine in translational cancer research
Selected abstract presentations
09:45 - 10:05
Tania Løve Aaes
RIPK3-dependent necroptosis is immunogenic – a new target in anti-cancer therapy?
10:05 - 10:25
Celine Everaert
Decoding cancer transcriptomes using public RNA sequencing data
10:25 - 10:35
Company presentation (Perkin Elmer)
10:35 - 10:50
Short abstract presentations 1
10:50 - 11:20
Coffee break
Keynote speaker
11:20 - 12:05
Peter Friedl (Radboudumc, Nijmegen/MD Anderson Cancer Center, Houston)
Intravital imaging of cancer invasion, metastasis and resistance to therapy
Selected abstract presentations
12:05 - 12:25
Joke Tommelein
Radiotherapy-induced damage to cancer-associated fibroblasts promotes colorectal cancer progression through IGF-1/AKT signalling
12:25 - 12:45
Anje Cauwels
AcTakine strategy for safe systemic application of cytokines in cancer immunotherapy, proof of principle using a type I IFN-based AcTaferon
12:45 - 13:45
Lunch
Selected abstract presentations
13:45 - 14:05
Sofie Peirs
Targeting BET family proteins improves the efficacy of ABT-199 in T-cell acute lymphoblastic leukemia
14:05 - 14:25
Niek Sanders
Xenogeneic vascular endothelial growth factor-2 vaccination in tumor bearing mice
14:25 - 14:35
Company presentation (AstraZeneca)
Is Immuno-oncology therapy the Holy Grail for cancer treatment?
14:35 - 15:05
Short abstract presentations 2
15:05 - 15:40
Coffee break
Selected abstract presentations
15:40 - 16:00
Renate De Smedt
Exploring the role of the PHF6 tumor suppressor gene in DNA repair in T-cell acute lymphoblastic leukemia
16:00 - 16:10
Company presentation (Biocartis)
Selected abstract presentations
16:10 - 16:30
Mattias Van Heetvelde
Thorough Second hit analysis in BRCA1/2 associated breast cancer
16:30 - 16:50
Annemieke Madder
Furan-based crosslinking in situ: seizing ligand-receptor complexes in the act
16:50 - 17:10
Laurence Bertier
Nanobody footprinting of cortactin in cancer cell invasion
17:10 - 17:40
Short abstract presentations 3
17:40 - 18:00
Final conclusions, announcements of awards

Program 2015

08:45 - 09:00
Opening
09:00 - 09:40
Jacky Goetz (INSERM, Strassbourg)
Looking at tumor invasion and angiogenesis from a biomechanical and correlative point of view
Selected abstract presentations
09:40 - 10:00
Niels Vandamme
Zeb proteins dictate functional and phenotypic heterogeneity in melanoma
10:00 - 10:20
Dmitri Krysko
Targeting necroptosis is a novel approach for cancer therapy
10:20 - 10:25
Company presentation (Biogazelle)
10:25 - 10:50
Short abstract presentations (10)
10:50 - 11:10
Coffee break
11:10 - 11:50
Alexandra Van Keymeulen (ULB, Brussels)
Using lineage tracing and clonal analysis to unravel mammary gland cell hierarchy and breast cancer initiation
11:50 - 11:55
Company presentation (Bio-Rad)
Selected abstract presentations
11:55 - 12:15
Hetty Helsmoortel
LIN28B acts as major regulator of a fetal transcriptional network in the stem cell disease juvenile myelomonocytic leukemia
12:15 - 12:35
Tom Van Nieuwenhuysen
TALEN mediated mutation of APC in Xenopus tropicalis as a powerful model for Wnt driven cancer and Familial Adenomatous Polyposis (FAP)
12:35 - 13:45
Lunch
Selected abstract presentations
13:45 - 14:05
Irina Lambertz
Upregulation of MAPK negative feedback regulators and RET in mutant ALK neuroblastoma: implications for targeted treatment
14:05 - 14:25
Lore Lapeire
Cancer-associated adipose tissue promotes breast cancer progression by paracrine Oncostatin M and STAT3 signaling
14:25 - 14:30
Company presentation (Miltenyi)
14:30 - 15:00
Short abstract presentations (12)
15:00 - 15:30
Coffee break
15:30 - 16:10
Katleen De Preter (UGent)
Omics mining of aggressive neuroblastoma tumors: three roads lead to the DNA repair pathway as new vulnerable node for therapy
Selected abstract presentations
16:10 - 16:30
Yasmine Van Caeneghem
Expression of a chimeric antigen receptor in hematopoietic precursor cells inhibits the generation of a diverse T cell receptor repertoire and induces T Cell Receptor/CD3 negative, CD4 CD8 negative T cells
16:30 - 16:50
Xavier Verhelst
Assessment of serum glycomics (glycocirrhotest) for risk prediction of hepatocellular carcinoma development in patients with cirrhosis
16:50 - 17:10
Liv Veldeman
Development of a dedicated breast couch for prone breast and lymph node irradiation to improve patient comfort and reduce radiation-induced toxicity
17:10 - 17:15
Company presentation (AstraZeneca)
17:15 - 17:50
Short abstract presentations (12)
17:50 - 18:00
Final conclusions, announcements of awards

Program 2014

08:45 - 09:00
Opening
Selected abstract presentations
09:00 - 09:20
Anneleen Beckers
A novel MYCN/ miR-26a-5p/ LIN28B regulatory axis underlies MYCN‑driven LIN28B upregulation during mouse neuroblastoma development
09:20 - 09:40
Bieke Decaesteker
SOX11 is a lineage-survival oncogene in neuroblastoma
09:40 - 10:00
Elly De Vlieghere
Micro-particle encapsulated carcinoma-associated fibroblast (CAF) deceive and redirect disseminated cancer cells
10:00 - 10:40
Short abstract presentations
10:40 - 11:00
Coffee break
Selected abstract presentations
11:00 - 11:20
Evelien Mets
MicroRNA-128-3p is a novel oncomir targeting PHF6 in T-cell acute lymphoblastic leukemia
11:20 - 11:40
Evelyne Meyer
Optimalization and characterization of a novel intraductal mouse mammary tumor model
11:40 - 12:00
Geertrui Denecker
Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression
12:00 - 12:40
Short oral abstract presentations (part II)
12:40 - 13:30
Lunch
Selected abstract presentations
13:30 - 13:50
Heleen Dewitte
The bubble breakthrough in cancer immunotherapy: the use of mrna sonoporation in dendritic cell-based cancer vaccination
13:50 - 14:10
Jan Van Deun
A comparative study of four isolation methods for exosomes from cell culture models
14:10 - 14:30
Kaat Durinck
Expanding the TLX1-regulome in T-cell acute lymphoblastic leukemia towards long non-coding RNAs
14:30 - 14:50
Pieter Colin
A model-based analysis of IPEC dosing of paclitaxel in rats: "less is more"
14:50 - 15:10
Pieter Mestdagh
LncRNA expression landscaping in cancer identifies novel lineage survival oncogenes in melanoma
15:10 - 15:30
Shana Claeys
Green tea compound EGCG activates HBP1: an ALK downstream suppressor gene in neuroblastoma
15:30 - 15:50
Sofie Peirs
ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in early immature T-cell acute lymphoblastic leukemia
15:50 - 16:10
Coffee break
Selected abstract presentations
16:10 - 16:30
Tom Claeys
Metastasis-directed therapy for oligometastic recurrence in non-castrate prostate cancer patients
16:30 - 16:50
Vanessa Andries
Role of NANOS family members in tumor progression
16:50 - 17:10
Yves-Paul Vandewynckel
Temporal dynamics and therapeutic potential of the unfolded protein response in hepatocellular carcinoma
17:10 - 17:50
Short abstract presentations
17:50 - 18:05
Final conclusions, announcements of awards
18:05 - end
Communicake (drinks, cake and communication)

Program 2012

08:45 - 09:00
Opening
Session I: Imaging in cancer research
09:00 - 09:30
Christian Van Hove (MEDISIP)
INFINITY: The small animal imaging facility of Ghent University
09:30 - 10:00
Wim Ceelen (Departement of Surgery)
Kinetic modelling of dynamic contrast enhanced MR data: a tool for noninvasive assessment of tumour vascular physiology
10:00 - 10:30
Short oral abstract presentations (part I)
10:30 - 10:50
Coffee break & poster viewing
Selected oral abstract presentations
10:50 - 11:05
Kaat Durinck
Functional interplay of NOTCH1 and PHF6: balancing between normal T-cell development and T-ALL
11:05 - 11:20
Astrid De Boeck
Bone marrow-derived mesenchymal stem cells drive colorectal cancer progression: implication of a paracrine neuregulin 1/HER3 activation loop
11:20 - 11:35
Candy Kumps
Transcriptome analysis following ALK abrogation provides insights in the downstream signaling pathways in human and murine neuroblastoma cells
11:35 - 11:50
An Hendrix
Rab27B, an ex(o)citing driver of breast cancer growth, invasion and metastasis
11:50 - 12:20
Short oral abstract presentations (part II)
12:20 - 13:30
Lunch & poster viewing
Session II: Tumor environment
13:30 - 14:00
Olivier De Wever (Laboratory of Experimental Cancer Research)
The tumor ecosystem: a source for therapeutic targets and biomarker discovery
14:00 - 14:30
Karim Vermaelen (Departement of Pulmonary Medicine)
Phenotypic, functional and epigenetic modulation of dendritic cells by the murine lung tumor environment
Selected oral abstract presentations
14:30 - 14:45
Ann Van Hecke
Research protocol: Adherence in patients using oral tyrosine kinase inhibitors: development of an intervention to improve adherence
14:45 - 15:00
E. Decoene
Development of evidence-based guidelines for a nurse consultation in a breast unit
15:00 - 15:15
Gwen Sys
Tumour grafts derived from sarcoma patients retain tumour morphology, viability, invasion potential, and indicate disease outcome in the chick chorioallantoic membrane model
15:15 - 15:30
Piet Ost
Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy
15:30 - 15:45
Isabel Van Audenhoven
Fascin loss-of-function by intracellular delocalisation with nanobodies
15:45 - 16:15
Coffee break
Session III: Emerging technologies in cancer research
16:15 - 16:45
Marleen Van Troys (Departement of Biochemistry)
Quantitative analysis of cell migration dynamics in 3D matrices at higher throughput
16:45 - 17:15
Pieter Mestdagh (Center for Medical Genetics)
Exploratory tools to study non-coding RNA in cancer
Session IV: Support in cancer research
17:15 - 17:45
Sofie Bekaert (BIMETRA)
BIMETRA: facilitation of translational research @ campus
17:45 - 18:00
Final conclusions, announcements of awards

het Pand, Ghent University

Pand 1
P7 - Sint-Michiels
By public transport

• from train station Gent St-Pieters:

    tram 1 (every 6 minutes) or tram 24 (every 20 minutes).

Exit at Korenmarkt.

• from train station Gent Zuid:

    bus 17 (every 30 minutes).

Exit at Korenmarkt.

By car

Follow the parking signage to parking P7 Sint-Michiels. The parking is located at 50 meter from Het Pand.

Take the exit Onderbergen and you come out in the Wilderoosstraat, opposite Het Pand.

An alternative parking is P8 Ramen. From here it's about 5 minutes on foot to Het Pand.

Registration is free but obligatory

Registration is now closed

Before submitting your abstract, please register for the meeting.

At least 12 abstracts for short oral presentation (15 min. + 5 min. discussion) and
30 abstracts for storm session presentations (2-4 min.) will be selected.

Awards will be given for best oral and best storm session presentations.

Abstracts should be no more than 250 words, written in English.

Dead-line for abstract submission extended until February 15th, 2016.

Abstracts will be published as pdf-files on the OncoPoint website:

Please consult your co-authors on possible intellectual property issues. An abstract book will also be made available on-site.

The abstract submission deadline has passed.